Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Boston's Watchman finally gets US green light

This article was originally published in Clinica

Executive Summary

It has been a long road to approval, but Boston Scientific’s Watchman has finally got the go-ahead from the US FDA. The product is designed to close the left-atrial appendage (LAA), a bulge in the wall of the left atrium of the heart where blood clots can form in patients with atrial fibrillation, and therefore prevent ischemic stroke.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts